Frontlight ResearchEarly access
CompletedPhase 3
A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD
Key facts
- Who runs it
- Lipocine Inc.
- Where
- Anahiem, Atlanta, Beaumont, Canoga Park, Decatur, Houston, Idaho Falls, Kansas City, Las Vegas, League City, Media, Miami, Miami Gardens, Monroe, New Orleans, Provo, and Savannah, United StatesSee the 18 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 90 people enrolled
- Started
- 16 Jun 2025
- Ended
- 17 Feb 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- LPCN 1154A
- Placebo
- Record updated
- 24 February 2026
Who can take part
- Age
- 15 years to 45 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Are female between 15 and 45 years of age, inclusive
- Have had a depressive episode that began no earlier than third trimester and later than the first 4 week following delivery
- Are < 12 months postpartum at Screening
- Hamilton Depression Rating Scale (HAM-D) 17-item score indicative of severe depression
Who cannot take part
- Have a history of bipolar disorder, schizophrenia or schizoaffective disorder
- Have a history of suicidal behavior within 1 year
- Have a history of seizure within 6 months of Screening
- Are currently experiencing active psychosis per Investigator assessment
Where in United States
- Advanced Research CenterAnahiem, United States
- Atlanta Behavioral ResearchAtlanta, United States
- Gadolin ResearchBeaumont, United States
- Alliance Research InstituteCanoga Park, United States
- CenExel Research CenterDecatur, United States
- New Dawn Wellness and Medical CenterHouston, United States
- Clinical Research PrimeIdaho Falls, United States
- Cypress Medical Research Center, LLCKansas City, United States
- Oasis Clinical ResearchLas Vegas, United States
- Maximos Ob/GynLeague City, United States
- Suburban Research AssociatesMedia, United States
- D&H National Research CentersMiami, United States
- MedOne Clinical Research LLCMiami, United States
- Meridian International ResearchMiami Gardens, United States
- Monroe Biomedical ResearchMonroe, United States
- Best Clinical TrialsNew Orleans, United States
- Populace ResearchProvo, United States
- CenExel Research CenterSavannah, United States
About the trial
What the trial wants to find out
The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD). The trial aims to determine:
Read full original descriptionShow less
* If LPCN 1154A reduces depressive symptoms in subjects with severe PPD * How well LPCN 1154A is tolerated and what side effects it may cause * If LPCN 1154A reduces anxiety symptoms in subjects with severe PPD
The 2 groups in the trial
- LPCN 1154A TabletsTreatment being tested
LPCN 1154A
Treatment: LPCN 1154A
- Placebo TabletsPlacebo, for comparison
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Randomized, Blinded, Placebo-Controlled Study to Evaluate the Saftey and Efficacy of Oral LPCN 1154A in Women With Postpartum Depression
- Record updated
- 24 February 2026